Hypera S.A
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamm… Read more
Hypera S.A (HYPE3) - Net Assets
Latest net assets as of September 2025: R$12.26 Billion BRL
Based on the latest financial reports, Hypera S.A (HYPE3) has net assets worth R$12.26 Billion BRL as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (R$28.53 Billion) and total liabilities (R$16.27 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | R$12.26 Billion |
| % of Total Assets | 42.96% |
| Annual Growth Rate | 35.02% |
| 5-Year Change | 30.96% |
| 10-Year Change | 50.7% |
| Growth Volatility | 388.63 |
Hypera S.A - Net Assets Trend (2005–2024)
This chart illustrates how Hypera S.A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Hypera S.A (2005–2024)
The table below shows the annual net assets of Hypera S.A from 2005 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | R$12.10 Billion | +5.07% |
| 2023-12-31 | R$11.52 Billion | +8.09% |
| 2022-12-31 | R$10.66 Billion | +8.36% |
| 2021-12-31 | R$9.83 Billion | +6.41% |
| 2020-12-31 | R$9.24 Billion | +6.09% |
| 2019-12-31 | R$8.71 Billion | +5.35% |
| 2018-12-31 | R$8.27 Billion | +6.85% |
| 2017-12-31 | R$7.74 Billion | -11.15% |
| 2016-12-31 | R$8.71 Billion | +8.44% |
| 2015-12-31 | R$8.03 Billion | +7.42% |
| 2014-12-31 | R$7.48 Billion | +5.61% |
| 2013-12-31 | R$7.08 Billion | +3.06% |
| 2012-12-31 | R$6.87 Billion | +3.35% |
| 2011-12-31 | R$6.65 Billion | +31.37% |
| 2010-12-31 | R$5.06 Billion | +48.02% |
| 2009-12-31 | R$3.42 Billion | +78.33% |
| 2008-12-31 | R$1.92 Billion | +176.68% |
| 2007-12-31 | R$692.69 Million | +1752.11% |
| 2006-12-31 | R$37.40 Million | -7.20% |
| 2005-12-31 | R$40.30 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Hypera S.A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 152488300000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | R$1.51 Billion | 12.48% |
| Common Stock | R$9.71 Billion | 80.24% |
| Other Comprehensive Income | R$903.74 Million | 7.47% |
| Total Equity | R$12.10 Billion | 100.00% |
Hypera S.A Competitors by Market Cap
The table below lists competitors of Hypera S.A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Pigeon Corporation
F:9N3
|
$1.04 Billion |
|
EVN AG
VI:EVN
|
$1.04 Billion |
|
Great Lakes Dredge & Dock
NASDAQ:GLDD
|
$1.04 Billion |
|
Global Health Limited
NSE:MEDANTA
|
$1.04 Billion |
|
MicroPort Endovascular MedTech Ltd
SHG:688016
|
$1.04 Billion |
|
Genimous Technology Co Ltd
SHE:000676
|
$1.04 Billion |
|
Runjian Communication Co Ltd Class A
SHE:002929
|
$1.04 Billion |
|
Anhui Guangxin Agrochemical Co Ltd
SHG:603599
|
$1.04 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hypera S.A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 11,504,124,000 to 12,096,281,000, a change of 592,157,000 (5.1%).
- Net income of 1,340,990,000 contributed positively to equity growth.
- Dividend payments of 787,286,000 reduced retained earnings.
- Share repurchases of 55,807,000 reduced equity.
- New share issuances of 13,246,000 increased equity.
- Other comprehensive income decreased equity by 7,404,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | R$1.34 Billion | +11.09% |
| Dividends Paid | R$787.29 Million | -6.51% |
| Share Repurchases | R$55.81 Million | -0.46% |
| Share Issuances | R$13.25 Million | +0.11% |
| Other Comprehensive Income | R$-7.40 Million | -0.06% |
| Other Changes | R$88.42 Million | +0.73% |
| Total Change | R$- | 5.15% |
Book Value vs Market Value Analysis
This analysis compares Hypera S.A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.13x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 168.66x to 1.13x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | R$0.13 | R$21.42 | x |
| 2006-12-31 | R$0.12 | R$21.42 | x |
| 2007-12-31 | R$2.18 | R$21.42 | x |
| 2008-12-31 | R$4.83 | R$21.42 | x |
| 2009-12-31 | R$7.93 | R$21.42 | x |
| 2010-12-31 | R$9.02 | R$21.42 | x |
| 2011-12-31 | R$9.95 | R$21.42 | x |
| 2012-12-31 | R$10.23 | R$21.42 | x |
| 2013-12-31 | R$10.97 | R$21.42 | x |
| 2014-12-31 | R$11.61 | R$21.42 | x |
| 2015-12-31 | R$12.47 | R$21.42 | x |
| 2016-12-31 | R$13.57 | R$21.42 | x |
| 2017-12-31 | R$12.16 | R$21.42 | x |
| 2018-12-31 | R$12.93 | R$21.42 | x |
| 2019-12-31 | R$13.61 | R$21.42 | x |
| 2020-12-31 | R$14.48 | R$21.42 | x |
| 2021-12-31 | R$15.37 | R$21.42 | x |
| 2022-12-31 | R$16.66 | R$21.42 | x |
| 2023-12-31 | R$18.04 | R$21.42 | x |
| 2024-12-31 | R$18.96 | R$21.42 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hypera S.A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 11.09%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 18.02%
- • Asset Turnover: 0.30x
- • Equity Multiplier: 2.03x
- Recent ROE (11.09%) is above the historical average (10.90%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 76.92% | 8.94% | 1.35x | 6.39x | R$26.97 Million |
| 2006 | -7.84% | -0.77% | 1.19x | 8.54x | R$-6.67 Million |
| 2007 | 6.09% | 3.97% | 0.54x | 2.85x | R$-27.03 Million |
| 2008 | -10.85% | -15.59% | 0.37x | 1.86x | R$-399.53 Million |
| 2009 | 8.50% | 14.85% | 0.32x | 1.77x | R$-51.62 Million |
| 2010 | 5.18% | 9.38% | 0.28x | 1.97x | R$-244.01 Million |
| 2011 | -0.82% | -1.64% | 0.25x | 2.01x | R$-719.24 Million |
| 2012 | 2.97% | 5.26% | 0.31x | 1.84x | R$-482.92 Million |
| 2013 | 3.63% | 6.03% | 0.34x | 1.77x | R$-451.14 Million |
| 2014 | 5.39% | 14.55% | 0.20x | 1.86x | R$-344.90 Million |
| 2015 | 6.97% | 18.94% | 0.19x | 1.97x | R$-243.17 Million |
| 2016 | 13.52% | 36.48% | 0.28x | 1.31x | R$306.90 Million |
| 2017 | 12.47% | 27.57% | 0.35x | 1.31x | R$191.17 Million |
| 2018 | 13.66% | 30.33% | 0.35x | 1.28x | R$302.83 Million |
| 2019 | 13.36% | 35.33% | 0.28x | 1.37x | R$293.03 Million |
| 2020 | 14.02% | 31.67% | 0.24x | 1.87x | R$371.04 Million |
| 2021 | 13.54% | 22.40% | 0.30x | 2.02x | R$347.55 Million |
| 2022 | 15.94% | 22.48% | 0.32x | 2.23x | R$632.12 Million |
| 2023 | 14.32% | 20.82% | 0.32x | 2.13x | R$497.55 Million |
| 2024 | 11.09% | 18.02% | 0.30x | 2.03x | R$131.36 Million |
Industry Comparison
This section compares Hypera S.A's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $286,516,000
- Average return on equity (ROE) among peers: 15.17%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hypera S.A (HYPE3) | R$12.26 Billion | 76.92% | 1.33x | $1.04 Billion |
| Blau Farmacêutica S.A (BLAU3) | $80.58 Million | 20.94% | 2.25x | $48.45 Million |
| Ouro Fino Saúde Animal Participações S.A (OFSA3) | $492.45 Million | 9.40% | 0.77x | $32.46 Million |